Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E B Rubenstein

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Cancer|June 1, 1993
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancerE B Rubenstein, K Rolston, R S Benjamin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopeniaL S Elting, E B Rubenstein, C G Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patientsJ Klastersky, M Paesmans, E B Rubenstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2000
Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of careL S Elting, E B Rubenstein, K Rolston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1995
Vascular access by physician assistants: evaluation of an implantable peripheral port system in cancer patientsE B Rubenstein, A Fender, K V Rolston, et al.
Journal of Pain and Symptom Management|November 9, 2000
Identifying risk factors for imminent death in cancer patients with acute dyspneaC P Escalante, C G Martin, L S Elting, et al.
Cancer|January 5, 1999
Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practiceL S Elting, E B Rubenstein, D Kurtin, et al.
Cancer|September 15, 1996
Dyspnea in cancer patients. Etiology, resource utilization, and survival-implications in a managed care worldC P Escalante, C G Martin, L S Elting, et al.
Cancer|March 15, 1997
Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study GroupE B Rubenstein, R J Gralla, J D Hainsworth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2010
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantationS A Giralt, K F Mangan, R T Maziarz, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Cancer|June 1, 1993
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancerE B Rubenstein, K Rolston, R S Benjamin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopeniaL S Elting, E B Rubenstein, C G Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patientsJ Klastersky, M Paesmans, E B Rubenstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2000
Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of careL S Elting, E B Rubenstein, K Rolston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1995
Vascular access by physician assistants: evaluation of an implantable peripheral port system in cancer patientsE B Rubenstein, A Fender, K V Rolston, et al.
Journal of Pain and Symptom Management|November 9, 2000
Identifying risk factors for imminent death in cancer patients with acute dyspneaC P Escalante, C G Martin, L S Elting, et al.
Cancer|January 5, 1999
Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practiceL S Elting, E B Rubenstein, D Kurtin, et al.
Cancer|September 15, 1996
Dyspnea in cancer patients. Etiology, resource utilization, and survival-implications in a managed care worldC P Escalante, C G Martin, L S Elting, et al.
Cancer|March 15, 1997
Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study GroupE B Rubenstein, R J Gralla, J D Hainsworth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2010
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantationS A Giralt, K F Mangan, R T Maziarz, et al.
Pageof 4